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BACKGROUND: Evidence for the efficacy of late effects surveillance in adult cancer survivors is lacking and there is little agreement
among clinicians on appropriate follow-up care.
METHODS: We report the views of both cancer experts and general practitioners (GPs) on long-term follow-up provision for cancer
survivors, focussing on the 18–45 years age group. A total of 421 cancer experts (36% haematologists, 33% oncologists,
18% surgeons, 10% nurses, 2% other) and 54 GPs responded to a structured online survey. Reasons for follow-up care (clinical
or supportive); advantages and disadvantages of follow-up in primary care; current practice; and resources required for a quality
follow-up service were assessed.
RESULTS: Clinicians valued clinical reasons for follow-up more highly than supportive reasons (Po0.001). Learning more about late
effects and checking for cancer recurrence were rated as the most important reasons for follow-up by cancer experts and GPs.
A total of 85% of cancer specialists hold follow-up consultations alongside patients on active treatment. Cancer experts agreed that
primary care follow-up would increase their availability for acute oncological care, but reduce information on late effects. The most
important resource to provide a quality follow-up service was specialist nursing support (91%).
CONCLUSIONS: Follow-up guidelines that include late effects surveillance are needed. Where and who should deliver this care requires
further debate.
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The prognosis of many cancers is steadily improving with over
50% of adult patients expected to survive for at least 5 years,
regardless of age of onset (Cancer Research UK, 2008a). The most
common malignancies in younger adults (aged 18–45 years) are
breast cancer, germ cell tumours, lymphoma and leukaemia.
Prognosis depends on tumour type, stage at diagnosis, and age at
onset, with most cancers in younger adulthood having relatively
good 5-year survival rates. For example, the 5-year survival
probabilities for those aged 15–39 years (age range presented from
data source) at diagnosis of breast or testicular cancers are 76 and
97%, respectively (Cancer Research UK, 2008b).
Despite the fact that many patients with neoplastic disease are
successfully treated for their initial disease, cancer treatments may
be associated with a variety of long-term side effects termed as ‘late
effects’. These can be functional (for example, amputation,
stomas), psychological (for example, anxiety, depression) or
physical (for example second malignancy, thyroid disease, cardiac
or respiratory dysfunction). Most of our understanding of late
effects comes from the paediatric setting, in which it has been
estimated that as many as 74% of long-term childhood survivors
develop a chronic illness as a result of their original disease or
treatment (Oeffinger et al, 2006). As a result, paediatricians have
developed follow-up guidelines (Children’s Oncology Group, 2004;
Scottish Intercollegiate Guidelines Network, 2004; Skinner et al,
2005). In contrast, in the adult cancer setting, there are only a few
national guidelines for clinicians on the identification or manage-
ment of late effects. Exceptions include the Royal College of
Physicians’ guidance on managing an early menopause in young
women (Report of a Working Party November 2007 et al, 2008)
and from a UK Expert Group, guidance for the management of
breast cancer treatment-induced bone loss (Reid et al, 2008).
Recent documents, including the NICE Children’s and Young
People’s Improving Outcomes Guidance (National Institute for
Health and Clinical Excellence, 2005) and the National Cancer
Survivorship Initiative born out of the Cancer Reform Strategy
(Department of Health, 2007), both highlight the importance of
long-term follow-up. Nevertheless, there is a paucity of evidence
examining the efficacy of long-term follow-up in identification of
late effects, particularly in younger adults who are likely to have
more complex needs in terms of fertility, duration of survival,
employment and family issues. Furthermore, the existing guide-
lines are essentially consensus rather than evidence-based. It is not
clear, for example, what oncologists regard as clinically appro-
priate follow-up care. Anecdotal evidence suggests that clinical
practice differs between cancer networks and is based on
preferences of individual clinicians, even within the same tumour
specialty.
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The number of people in the United Kingdom living with and
beyond cancer has been estimated as approximately two million,
representing almost 4% of our population (Maddams et al, 2009).
Currently, we have no information on the proportion of indiv-
iduals who are disease-free, who are receiving regular follow-up or
who have been discharged from the specialist centre. With the
mounting burden of cancer survivors, it is likely that general
practitioners (GPs) will take on more responsibility for routine
follow-up for this population of patients, but it is unclear whether
the primary care sector is either willing or able to take this on.
However, in a rigorous trial of GP versus hospital follow-up of
breast cancer, Grunfeld et al, 1996 reported that the majority of
GPs wished to provide follow-up as long as certain provisos were
assured. This study was limited only to breast cancer survivors and
did not include late effects surveillance.
The aims of this study therefore were to determine and compare
clinicians’ views of long-term follow-up care of younger adult
survivors of common cancers (breast, germ cell, lymphoma and
leukaemia) including reasons for follow-up care, advantages and
disadvantages of follow-up in primary care, current practice, and
the requirements for additional resources and supportive services.
MATERIALS AND METHODS
An anonymous e-survey was targeted at cancer experts (oncolo-
gists, haematologists, surgeons and cancer nurses) who care for or
specialise in breast cancer, lymphoma, leukaemia and germ cell
malignancies, and at GPs (the questionnaire is available from
authors on request). It was available online using an electronic web
link in September and October 2007. Web links were sent by email
through distribution lists and cascaded on. With this design, we
are not able to estimate a response rate for this study. The initial
invitation emails were endorsed and distributed by: the National
Cancer Research Institute’s Breast and Testis Clinical Studies
Groups; the Royal College of Pathologists (list of haemato-
logists); the British National Lymphoma Investigation; the
National Cancer Network Lead Nurse Director (to expert cancer
nurses); the Sheffield Primary Care Trust (to Sheffield General
Practitioners). An initial invitation and two reminders were sent,
except for haematologists who received only one reminder in an
electronic newsletter from the Royal College of Pathologists.
In a preface to the survey, cancer survivors were defined as
being disease-free and a minimum of 2 years from diagnosis. We
also defined late effects as ‘physical and psychological problems
that can occur months or years after the completion of cancer
treatment.’ We particularly asked respondents to focus on the care
and management of adults aged between 18–45 years, as younger
adults have historically been the explicit focus of our previous
research and clinical interest. Cancer experts were specifically
asked to select their main tumour group (breast, lymphoma,
leukaemia or germ cell) and respond to questions addressing the
follow-up care of the selected tumour-specific cancer survivors.
Given that the focus of the survey was service evaluation, ethics
committee approval was not required, although we sought local
approval for the GP survey to access Sheffield GPs through the
Sheffield PCT’s local medical committee.
The questionnaire was organised around the following sections:
1. Demographic information. Gender, profession, number of years
of experience.
2. Reasons for attending follow-up care. Respondents rated the
importance of follow-up on two scales measuring clinical care
(five items; for example, cancer-related medical care) and
supportive care (four items; for example, psychosocial, health
behaviour advice) (adapted from (Absolom et al, 2006)). Items
were rated on five-point scales (1–5) with higher scores
indicating more importance. For analysis, the two categories
important/very important have been combined, and this
proportion has been reported along with raw number of
responses and confidence intervals.
3. Advantages and disadvantages of follow-up in primary care. We
listed six possible advantages (for example, least expensive
option, allows cancer specialist to focus on acute care, easier for
patients to ask GP’s advice) and five possible disadvantages of
follow-up in primary care (for example, too many calls on GP’s
time, loss of late-effects information, lack of expertise in
primary care). Items were developed in consultation with local
GPs, oncologists and haematologists. Items were rated on five-
point scales (1–5) with higher scores indicating more
agreement. For analysis, the categories agree/strongly agree
have been combined, and this proportion has been reported
with the raw number of responses and confidence intervals.
4. Current clinical practice. Respondents were asked whether they
used a tumour-specific follow-up protocol. Cancer experts were
additionally asked about their current clinical practice, such as
organisation of follow-up care and use of protocols for
discharging cancer survivors (yes/no responses).
5. Resources required to provide a quality follow-up service.
We listed five possible resources needed to provide a mean-
ingful follow-up service (for example, standardised guidelines;
financial resources; specialist nursing support) (yes/no
responses).
6. Open text boxes. They were available throughout for additional
comments and alternative suggestions.
Analysis
Sample size One of the aims of the survey was to estimate
clinicians’ views of long-term follow-up of cancer survivors.
Assuming that a proportion of 50% would respond positively to
a question on long-term follow-up, with 400 responders to the
survey, we would be able to estimate this proportion within±5%,
that is, 95% confidence interval from 45 to 55% (Altman et al,
2000). The online survey was technically managed by NHS
Healthcare Assessment and Training (HcAT) and anonymous
data were stored on an electronic database. Data were transferred
to the research team and analysed using SPSS v11 (SPSS Inc.,
Chicago, IL, USA) for Mac. Frequencies, means and ranges were
calculated, and where appropriate, rank scores were generated. w2,
t-tests and one way analysis of variance (ANOVA) with a post hoc
(Tukey’s) test to allow for multiple comparisons, were used to
compare differences of opinions between either (a) tumour group
specialist (for example, between breast cancer and germ cell
specialist) or (b) occupation groups (for example, between nurses
and oncologists). A P-value of o0.05 was regarded as statistically
significant. Ninety-five percent confidence intervals for the
proportions responding to a statement were also calculated
(Altman et al, 2000). Additional comments from open text boxes
were examined and themed using content analysis by two
independent coders and ratified by a third coder.
RESULTS
Sample
A total of 421 cancer experts and 54 GPs responded to this online
survey. Clinical and demographic details of respondents are shown
in Table 1.
Reasons for attending follow-up care
The mean scores for clinical and supportive reasons of follow-up
were compared within each professional group (Table 2). Overall,
clinicians rated clinical reasons for follow-up care more highly
than supportive reasons (3.8 vs 3.5, difference 0.3, 95% CI: 0.3–0.4;
Po0.001). One-way analysis of variance comparing mean scores
Clinicians’ views of follow-up after cancer
DM Greenfield et al
569
British Journal of Cancer (2009) 101(4), 568 – 574& 2009 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
between the professional groups also showed significant differ-
ences (Figure 1). Cancer nurses rated both clinical and supportive
reasons higher than did all other cancer experts but similar to
GPs. Surgeons rated supportive reasons significantly lower than
did haematologists but similar to oncologists.
Cancer experts rated learning more about late effects (76%,
316 out of 421; CI 72–80%) as the most important reason for
follow-up (Table 3). Checking for cancer recurrence was of
secondary importance (71%, 295 out of 421; CI 66–75%), whereas
94% (51 out of 54; CI 85–98%) of GPs rated checking for cancer
recurrence as the most important reason for follow-up, a
difference of 23% (CI 13–29%, Po0.001).
Content analysis on open-ended responses confirmed this basic
distinction between clinical and supportive reasons for follow-up
and included additional benefits such as monitoring outcomes,
research/clinical trial follow-up, improving staff morale, training
and fund-raising. The drawbacks of follow-up were categorised as:
patient related (false reassurance, perpetuates sick role, extra costs
incurred by the patient, anxiety, results in delays in investigations
or early detection); clinic related (expense, workload, lack of
evidence of follow-up efficacy); role related (lack of continuity
of care, responsibility falls mainly on inexperienced junior
medical staff, the role of the GP is undermined and there is an
inappropriate use of specialist time addressing general medical
problems). Benefits from hospital-based follow-up were identified
in terms of access to patient support groups and continuity of care
in the specialist setting.
Follow-up in primary care
Advantages A total of 69% of cancer experts (276 out of 402; CI
64–73%) agreed that the most important advantage of follow-up
in primary care is to enable cancer specialists to focus on acute
care (Figure 2). Other high-scoring advantages of primary care
Table 1 Characteristics of responders (n¼ 475)
All Haematologist Oncologist Surgeon Cancer nurse Other cancer experts GP
Sex
Male, n (%) 274 (58) 90 (59) 82 (59) 65 (88) 5 (11) 3 (30) 29 (54)
Female, n (%) 191 (40) 61 (40) 58 (41) 6 (8) 38 (86) 7 (70) 21 (39)
Undeclared/missing, n (%) 10 (2) 2(1) 0 (0) 3(4) 1 (2) 0 (0) 4 (7)
Total, n (%) 475 (100) 153 (100) 140 (100) 74 (100) 44 (99) 10 (100) 54 (100)
Years experience
Mean years, (n, s.d.) 19 (462, 8) 19 (151, 8) 18 (138, 7) 21 (71, 8) 15 (43, 7) 14 (10, 7) 21 (49, 9)
Hospital type
District general, n (%) 222 (53) 91 (60) 55 (39) 44 (60) 24 (55) 8 (80)
Metropolitan teaching, n (%) 181 (43) 56 (37) 79 (56) 28 (38) 18 (41) 0 (0)
Undeclared/missing, n (%) 18 (4) 6 (4) 6(4) 2 (3) 2 (5) 2 (20)
Total, n (%) 421 (100) 153 (101) 140 (99) 74 (101) 44 (101) 10 (100)
Tumour specialty
Breast cancer, n (%) 190 (45) 0 (0) 94 (67) 63 (85) 27 (61) 6 (60)
Lymphoma, n (%) 140 (33) 102 (67) 19 (14) 8 (11) 8 (18) 3 (30)
Leukaemia, n (%) 37 (9) 32 (21) 0 (0) 3 (4) 2 (5) 0 (0)
Germ cell, n (%) 21 (5) 0 (0) 19 (14) 0 (0) 2 (5) 0 (0)
Miscellaneous/missing, n (%) 33 (8) 19 (12) 8 (6) 0 (0) 5 (11) 1 (10)
Total, n (%) 421 (100) 153 (100) 140 (101) 74 (100) 44 (100) 10 (100)
GP status
Practice partners, n (%) 44 (81)
Salaried, n (%) 8 (15)
Undeclared, n (%) 2 (4)
Total, n (%) 54 (100)
Abbreviation: GP¼ general practitioner. % rounded up or down to nearest integer.
Table 2 Comparisons of clinical and supportive reasons for follow-up by professional group
Reasons for follow-up
Clinical Supportive
Mean
95% CI
Professional group (n) Mean s.d. Mean s.d. difference Lower Upper P-value
All clinicians (456) 3.8 0.8 3.5 0.7 0.3 0.4 0.3 o0.001
Haematologists (147) 3.8 0.8 3.5 0.6 0.3 0.4 0.2 o0.001
Oncologists (134) 3.7 0.7 3.3 0.7 0.3 0.4 0.3 o0.001
Surgeons (70) 3.7 0.8 3.2 0.8 0.5 0.6 0.4 o0.001
Cancer nurses (41) 4.1 0.5 3.9 0.6 0.2 0.3 0.1 0.001
GPs (54) 4.0 0.6 3.6 0.7 0.5 0.6 0.3 o0.001
Abbreviations: CI¼ confidence interval; GP¼ general practitioner. Scores were rated on a five-point (1–5) scale with a high score indicating more agreement. Clinical care
(for example, cancer-related medical care). Supportive care (for example, psychosocial, health behaviour advice). P-value from paired t-test.
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follow-up included ease of referring back to the specialist centre as
required (63%, 253 of 400; CI 58–68%) and the least expensive
option (55%, 221 out of 399; CI 50–60%). From the GP
perspective, their existing relationship with patients (82%, 40
out of 49; CI 69–90%), their accessibility (69%, 34 out of 49; CI
55–80%) and lower costs (66%, 33 out of 50; 52–78%) were
considered as distinct advantages of follow-up in primary care.
Statistically significant differences in mean scores between cancer
experts and GPs were observed for GP accessibility (2.6 vs 3.6,
difference 0.9, 95% CI: 1.3 to 0.7; Po0.001), GPs’ existing
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Figure 1 Scatter plots of scores for clinical and supportive reasons for follow-up by professional group. Scores were rated on a five-point (1–5) scale with
a high score indicating more agreement. Mean scores were compared between professional groups by a one-way ANOVA (analysis of variance). If the
overall one-way ANOVA was significant at the 0.05 level, then a series of pairwise multiple comparisons were made to determine which mean differences
using a post hoc (Tukey’s) test allowed for multiple comparisons. Significant differences between the mean scores by professional groups are indicated using
the following notation: H¼ haematologist, O¼ oncologist, S¼ surgeon, N¼ nurse, G¼GP. For example, for clinical care scores, the N above the
haematologist scatter plot implies significant differences between the mean haematologist and nurse scores, but none of the other professional groups.
Table 3 Reasons for attending follow-up: clinicians’ ratings
Item Scale
Rank
(cancer
experts)
% Cancer experts
reporting important
or very important
Rank
(GPs)
% GPs reporting
important or very
important
Learn more about late effects C 1 75.8 ¼ 3 83.3
Check for cancer recurrence C 2 70.8 1 94.4
Provide patients with information about potential late effects C 3 70.1 ¼ 3 83.3
Provide patients with psychological support S 4 69.6 5 79.6
Reassure patients about their health C 5 69.4 2 87.0
Provide patients with best medical care C 6 57.9 6 70.4
Give patients the opportunity to talk to staff who understand S 7 52.8 8 59.2
Advise patients on how to keep healthy S 8 41.6 7 64.8
Provide advise on everyday things such as insurance S 9 27.0 9 38.9
Abbreviations: C¼ clinical; GP¼ general practitioner; S¼ supportive.
Easier for patients to
seek GPs advice
Reduction in patient
anxiety
Ease of referring back if
necessary
Experts can focus on
acute care
GP’s know their patients
& can address issues
GPs have too many
other priorities
Least expensive option
Primary care budgets
inadequate
Loss of late effects
outcome data
Lack of expertise in
primary care
Increase in patient
anxiety
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Figure 2 Advantages and disadvantages of follow-up in primary care according to cancer experts.
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relationship with patients (2.9 vs 3.8, difference 0.9, 95% CI: 1.1
to 0.7; Po0.001) and reduction in patient anxiety (2.9 vs 3.4,
difference 0.4, 95% CI: 0.7 to 0.2; P¼ 0.001).
Content analysis of open-ended responses from cancer experts
identified other advantages which were categorised as patient
related (normalises the patient experience, encourages indepen-
dence from specialist team, reduces patient travel and cost); GP
skill related (more experience than cancer specialist in identifying
and managing common medical problems, health promotion
advice); systems related (knock on benefits in reducing cancer
waiting times for new referrals by releasing more appointments,
mechanisms for expediting direct referrals back to specialist care).
Content analysis of GPs’ open-ended responses identified
benefits of follow-up in primary care as patient related (giving
patients a choice) and role related. Several examples of role-related
benefits were proposed. For example, GPs are well placed to offer
supportive follow-up, including advice on health behaviours,
reassurance about health and everyday advice. In addition, GPs
may help to reduce the sense of abandonment that a patient may
feel after discharge from a specialist centre.
Disadvantages of follow-up in primary care A total of 84% (339
out of 402; CI 80–88%) of cancer experts rated the potential loss of
outcome data and information on late effects as the main
disadvantage of follow-up in primary care (Figure 2). Other key
disadvantages rated by cancer experts were the lack of expertise in
primary care (81%, 327 out of 405; CI 77–84%) and the potential
increase in patient anxiety (69%, 280 out of 405; CI 64–73%). In
comparison, 79% (41 out of 52; CI 66–88%) of GPs viewed
inadequate budgets, too many other demands on their time (77%,
40 out of 52; CI 64–86%) and lack of appropriate expertise (75%,
39 out of 52; CI 62–85%) as the main potential disadvantages
of follow-up in primary care. Statistically significant differences
in the ranking of disadvantages between cancer experts and GPs
were observed for inadequate primary care budgets (3.1 vs 3.8,
difference 0.8, 95% CI: 1.1 to 0.6; Po0.001), too many other
priorities for GPs (3.6 vs 3.9 difference 0.4, 95% CI: 0.6 to 0.1;
P¼ 0.005), loss of outcome data (4.1 vs 3.6, difference 0.4, 95% CI:
0.2–0.7; P¼ 0.001) and lack of expertise (4.1 vs 3.8, difference 0.3,
95% CI: 0.1–0.5; P¼ 0.018).
Content analysis on both cancer experts and GPs’ open-ended
responses identified other disadvantages, including patient-related
concerns (anxiety, choice, conveys notion of cure and false
reassurance), specialist-related concerns (patient trust), GP
organisation-related concerns (reticence, inadequate mechanisms
of re-referral, already have too many protocols, inadequate
resources) and GP skill-related concerns (delays in investigation
and re-referral, GP training and expertise deficit, lack of mutual
confidence between specialist and primary care).
Current clinical practice
None of the GPs reported using a tumour-specific follow-up
protocol (0%, 0 out of 55 CI 0–7%). This compared with 43% (176
out of 413; CI 38–47%) of cancer experts (76% (56 out of 74; CI
65–84%) surgeons, 58% (79 out of 137; CI 49–66%) oncologists,
51% (22 out of 43; CI 37–65%) nurses, 10% (15 out of 150; CI
6–16%) haematologists). Protocols were used by 62% (118 out of
190; CI 55–69%) of breast cancer experts, 84% (16 out of 19; CI
62–94%) of germ cell experts, 19% (26 out of 137; CI 13–26%) of
lymphoma experts and 19% (7 out of 37 CI 9–34%) of leukaemia
experts.
A total of 85% of cancer experts (331 out of 390; CI 81–88%)
reported seeing follow-up patients alongside those receiving active
treatment. This did not differ significantly by tumour group. Only
5% (14 out of 266) of cancer experts discharge patients at 2 years
from end of treatment; 60% (196 out of 324) discharge patients by
5 years from end of treatment (80% (119 out of 149; CI 73–86%),
71% (12 out of 17; CI 47–87%), 42% (45 out of 108; CI 33–51%)
and 32% (10 out of 31; CI 19–50%), respectively, for breast, germ
cell, lymphoma and leukaemia experts).
Resources required for a quality follow-up service for
cancer survivors
A total of 91% of respondents (405 out of 447; CI 88–93%) rated
specialist nursing support as the most important resource required
for a quality follow-up service. This was followed by financial
resources (84%, 372 out of 441 CI 81–87%) and standardised
guidelines (79%, 354 out of 449 CI 75–82%). The responses did
not differ significantly by professional or tumour group.
DISCUSSION
This survey specifically explored the views of clinicians from a
broad range of professional groups and from across several
tumour specialties towards follow-up services for younger adult
cancer survivors aged 18–45 years. Provision of long-term follow-
up care is topical and this survey coincides with national
developments to redesign the clinical service for cancer survivors.
We found that regardless of specialty, clinicians value clinical
reasons for follow-up more highly than supportive reasons, with
‘learning more about late effects’ as the top priority. Differing
expectations between patients and professionals may play a part,
with cancer specialists not feeling that offering supportive care is
part of their remit. Furthermore, cancer experts were particularly
concerned that transfer of care to the GP would result in the loss of
outcome data on late effects. The recent Department of Health
recall for breast screening of young women treated for Hodgkin’s
lymphoma with mantle radiotherapy (Department of Health, 2003)
is an example of why recording outcome data is important. All
clinicians agreed that follow-up in primary care would enable
cancer specialists to focus more on acute care. Notably, 91% of all
clinicians indicated that the most important resource to provide a
quality follow-up service is specialist nursing support.
Understandably, the delivery of acute care remains the number
one priority in cancer management. Improvements in palliative
and supportive care have been significant in recent years, whereas
follow-up programmes, where they exist, have focused on
detecting recurrence. Indeed, in our survey ‘checking for cancer
recurrence’ was identified as the most important reason for follow-
up by GPs and was also scored very highly by cancer experts. In
the immediate period after the end of treatment, there may be a
high risk of recurrence, with rates differing according to tumour
group; hence, this finding is unsurprising. However, justifying
follow-up mainly on the grounds of cancer recurrence surveillance
may be a false reassurance for patients, as most cases are detected
between scheduled follow-up appointments (Grunfeld et al, 1996).
As time since the end of treatment increases, recurrence rates
lessen. Follow-up will not reduce recurrence rates, although early
identification in some situations may influence the outcome
(Renehan et al, 2002) and the success or otherwise of salvage
options, as some relapses are curable (for example, lymphoma or a
loco-regional recurrence from breast cancer). Thus, research is
required to investigate the clinical effectiveness of follow-up
provision for cancer recurrence, as well as the screening for and
management of late effects.
Cancer experts and GPs both agree that late effects expertise in
primary care is currently insufficient and as such is currently a
distinct disadvantage of follow-up in this setting. A number of
advantages were identified, however, including GPs experience in
managing chronic illness, familiarity with their patients, geogra-
phical proximity and convenience. Furthermore, GPs identified
their own expertise as both provider of and referral to local
supportive care agencies. On the other hand, with only a small
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number of cancer survivors registered at each practice, following a
tumour-specific follow-up may not be feasible.
Whether the disadvantages of follow-up in primary care
outweigh the potential advantages is unclear, and likely to vary
depending on the underlying diagnosis and extent of earlier
treatment. A risk-adapted strategy with patients perceived at low
risk for recurrence and serious late effects might be best suited to
follow-up in primary care, whereas those with more complex cases
and those still at high risk of cancer recurrence may be better
served by hospital-based follow-up. A shared-care approach, with
the specialist centre prescribing appropriate medical surveillance
through a treatment summary and long-term follow-up care plan,
delivered by the GP, may prove an alternative model. The caveat
with any proposed model of follow-up is patient acceptability.
Results of a systematic review examining the evidence of
alternative models of follow-up in breast cancer (Montgomery
et al, 2007) indicated that different care options may be acceptable
to patients and may also be associated with other benefits.
Moreover, our survey of patients (Absolom et al) indicated that
cancer survivors would prefer follow-up to remain in the specialist
setting, although they might be willing to try alternative models.
In terms of current practice, 85% of cancer specialists surveyed
held follow-up consultations with cancer survivors alongside
patients on active treatment. Under these circumstances, most
follow-up patients receive short appointments, often with junior
medical staff, who, although capable, do not offer continuity.
Beaver and Luker (2005) found that, although breast cancer
survivors gained reassurance from a brief follow-up consultation
focusing on detection of recurrent disease, there were few
opportunities to meet their information and psychosocial needs.
Indeed, our parallel survey of long-term survivors (Absolom et al,
2009) indicated that patients themselves view clinical reasons for
follow-up more highly than supportive, indicating, perhaps, that
they have low expectations of receiving supportive care within the
current follow-up framework.
Results from our survey and those of others (Donnelly et al, 2007)
identified that most breast cancer experts are not discharging
patients at 3 years post diagnosis, as per the NICE 2002 guidelines
(National Institute for Clinical Excellence, 2002). Particular concerns
of experts rendering the guidelines obsolete include the need to
provide adequate guidance on long-term endocrine treatment
(where biologically appropriate), or on the risk-benefits of breast
reconstruction and available surgical options, areas generally
beyond the remit of follow-up in primary care and best addressed
in a specialist setting. The new updated NICE breast guidelines
(National Institute for Health and Clinical Excellence, 2009) have
been amended to address follow-up issues with a particular
recognition that follow-up care needs to be personalised.
Almost one-third of cancer experts who responded to this
survey were haematologists and, of note, only 10% reported using
a cancer-specific follow-up protocol. The long-term needs of, for
example, the haemato-oncology patient after stem cell transplanta-
tion conditioned with total body irradiation, are extremely
complex with almost any system and organ of the body at risk
of late effects (Socie´ et al, 2003; Tichelli et al, 2008), and important
sequelae may need to be addressed on a case by case basis.
Although essentially consensus rather than evidence-based, long-
term follow-up guidelines are used widely in a paediatric setting
(Children’s Oncology Group, 2004; UKCCSG Late Effects Group,
2005). These may provide a useful starting point to be adapted for
use in an adult oncology setting.
Our survey identified financial resources, standardised guide-
lines and late effects expertise, as the most important resources
required to provide a meaningful, quality follow-up service, with
specialist nursing support identified as the critical resource for
such a service. This is in concordance with the Cancer Reform
Strategy (Department of Health, 2007). There is a small body of
evidence indicating that nurse-led follow-up is clinically effective
and acceptable to the patient (Moore et al, 2002; Cox and Wilson,
2003; Knowles et al, 2007; Beaver et al, 2009), but more research is
needed in this area, particularly focussing on clinical effectiveness
of late effects surveillance.
Our survey had limitations. We were unable to establish a
response rate as the web link to the survey was distributed
electronically by e-mail and cascaded on through a variety of
mailings. Despite a sizeable sample, we were unable to ensure that
our survey respondents are representatives of the entire target
audience. In addition, the GPs in this survey are from one
geographic region only, and attitudes may vary from one region to
another, and between urban and rural practices.
Follow-up care is being increasingly recognised both nationally
(Department of Health, 2007) and internationally as a pressing
health issue (Grunfeld, 2006; Herbst et al, 2006). Long-term follow-
up for all cancer survivors, regardless of age, may change with
eventual recommendations from the National Cancer Survivorship
Initiative. As a baseline, the survivorship initiative acknowledges
that there are already a myriad of agencies offering supportive care,
including both professional and voluntary services, and is examin-
ing ways in which integrated pathways between supportive care and
clinical care can be developed. Rising numbers of cancer survivors
mean that the burden of care needs addressing and that any changes
require robust evaluation to examine both their clinical effectiveness
and acceptability. The findings from our survey highlight some
important priorities, needs and opinions amongst health care
providers around which new services need to be shaped.
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